MedTrace Logo

Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke

NCT04415164 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2021-04-09

No results posted yet for this study

Summary

The aim is to assess the effects and harms of Xueshuantong lyophilized powder versus placebo in patients with acute ischemic stroke when initiated within 72 hours of symptom onset.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Xueshuantong lyophilized powder

Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.

DRUG

Placebo

Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.

OTHER

Guidelines-based standard care

Guidelines-based standard care for acute ischemic stroke

Sponsors & Collaborators

  • Tianjin University of Traditional Chinese Medicine

    collaborator OTHER

  • Dongzhimen Hospital, Beijing

    lead OTHER

Principal Investigators

  • Ying Gao · Dongzhimen Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-29
Primary Completion
2022-10-31
Completion
2023-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04415164 on ClinicalTrials.gov